IMGT®, the international ImMunoGeneTics information system® 25 years on
Marie-Paule Lefranc,Véronique Giudicelli,Patrice Duroux,Joumana Jabado-Michaloud,Géraldine Folch,Safa Aouinti,Emilie Carillon,Hugo Duvergey,Amélie Houles,Typhaine Paysan-Lafosse,Saida Hadi-Saljoqi,Souphatta Sasorith,Gérard Lefranc,Sofia Kossida +13 more
TLDR
IMGT®, the international ImMunoGeneTics information system, is the global reference in immunogenetics and immunoinformatics and provides a high-quality and integrated system for analysis of the genomic and expressed IG and TR repertoire of the adaptive immune responses, including NGS high-throughput data.Abstract:
IMGT(®), the international ImMunoGeneTics information system(®)(http://www.imgt.org) is the global reference in immunogenetics and immunoinformatics. By its creation in 1989 by Marie-Paule Lefranc (Universite de Montpellier and CNRS), IMGT(®) marked the advent of immunoinformatics, which emerged at the interface between immunogenetics and bioinformatics. IMGT(®) is specialized in the immunoglobulins (IG) or antibodies, T cell receptors (TR), major histocompatibility (MH) and proteins of the IgSF and MhSF superfamilies. IMGT(®) is built on the IMGT-ONTOLOGY axioms and concepts, which bridged the gap between genes, sequences and 3D structures. The concepts include the IMGT(®) standardized keywords (identification), IMGT(®) standardized labels (description), IMGT(®) standardized nomenclature (classification), IMGT unique numbering and IMGT Colliers de Perles (numerotation). IMGT(®) comprises 7 databases, 17 online tools and 15,000 pages of web resources, and provides a high-quality and integrated system for analysis of the genomic and expressed IG and TR repertoire of the adaptive immune responses, including NGS high-throughput data. Tools and databases are used in basic, veterinary and medical research, in clinical applications (mutation analysis in leukemia and lymphoma) and in antibody engineering and humanization. The IMGT/mAb-DB interface was developed for therapeutic antibodies and fusion proteins for immunological applications (FPIA). IMGT(®) is freely available at http://www.imgt.org.read more
Citations
More filters
Journal ArticleDOI
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Christopher O. Barnes,Claudia A. Jette,Morgan E. Abernathy,Kim Marie A. Dam,Shannon R. Esswein,Harry B. Gristick,Andrey G. Malyutin,Naima G. Sharaf,Kathryn E. Huey-Tubman,Yu E. Lee,Davide F. Robbiani,Davide F. Robbiani,Michel C. Nussenzweig,Michel C. Nussenzweig,Anthony P. West,Pamela J. Bjorkman +15 more
TL;DR: Eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD are solved and rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use are provided.
Journal ArticleDOI
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
Christopher Southan,Joanna L. Sharman,Helen E. Benson,Elena Faccenda,Adam J. Pawson,Stephen P.H. Alexander,Peter Buneman,Anthony P. Davenport,John C. McGrath,John C. McGrath,John A. Peters,Michael Spedding,William A. Catterall,Doriano Fabbro,Jamie A. Davies +14 more
TL;DR: The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) database provides expert-curated molecular interactions between successful and potential drugs and their targets in the human genome, and provides an expanded substrate for the biennially published compendium, the Concise Guide topharmacology.
Journal ArticleDOI
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
Christopher O. Barnes,Anthony P. West,Kathryn E. Huey-Tubman,Magnus A.G. Hoffmann,Naima G. Sharaf,Pauline R. Hoffman,Nicholas Koranda,Harry B. Gristick,Christian Gaebler,Frauke Muecksch,Julio C. C. Lorenzi,Shlomo Finkin,Thomas Hagglof,Arlene Hurley,Katrina G. Millard,Yiska Weisblum,Fabian Schmidt,Theodora Hatziioannou,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Davide F. Robbiani,Michel C. Nussenzweig,Michel C. Nussenzweig,Pamela J. Bjorkman +24 more
TL;DR: Overall, the studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3-53/Vh3-66 and similarity to a SARS- coV VH 3-30 antibody, providing criteria for evaluating vaccine-elicited antibodies.
Journal ArticleDOI
A large peptidome dataset improves HLA class I epitope prediction across most of the human population.
Siranush Sarkizova,Siranush Sarkizova,Susan Klaeger,Phuong M. Le,Letitia Li,Giacomo Oliveira,Hasmik Keshishian,Christina R. Hartigan,Wandi Zhang,David A. Braun,Keith L. Ligon,Pavan Bachireddy,Pavan Bachireddy,Pavan Bachireddy,Ioannis K. Zervantonakis,Jennifer M. Rosenbluth,Tamara Ouspenskaia,Travis Law,Sune Justesen,Jonathan Stevens,William J. Lane,William J. Lane,Thomas Eisenhaure,Guang Lan Zhang,Guang Lan Zhang,Karl R. Clauser,Nir Hacohen,Nir Hacohen,Steven A. Carr,Catherine J. Wu,Derin B. Keskin +30 more
TL;DR: HLAthena is developed, providing allele-and-length-specific and pan-allele-pan-length prediction models for endogenous peptide presentation that correctly identified >75% of HLA-bound peptides that were observed experimentally in 11 patient-derived tumor cell lines.
Journal ArticleDOI
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Alexandra Snyder,Alexandra Snyder,Tavi Nathanson,Samuel Funt,Samuel Funt,Arun Ahuja,Jacqueline Buros Novik,Matthew D. Hellmann,Matthew D. Hellmann,Eliza Chang,Bulent Arman Aksoy,Hikmat Al-Ahmadie,Erik Yusko,Marissa Vignali,Sharon Benzeno,Mariel Elena Boyd,Meredith Maisie Moran,Gopa Iyer,Gopa Iyer,Harlan Robins,Elaine R. Mardis,Taha Merghoub,Jeff Hammerbacher,Jonathan E. Rosenberg,Dean F. Bajorin,Dean F. Bajorin +25 more
TL;DR: The results demonstrate the complex nature of immune response to checkpoint blockade and the compelling need for greater interrogation and data integration of both host and tumor factors.
References
More filters
Journal ArticleDOI
Entrez Gene: gene-centered information at NCBI
TL;DR: Entrez Gene is a step forward from NCBI's LocusLink, with both a major increase in taxonomic scope and improved access through the many tools associated with NCBI Entrez.
Journal ArticleDOI
IMGT®, the international ImMunoGeneTics information system®
Marie-Paule Lefranc,Véronique Giudicelli,Chantal Ginestoux,Joumana Jabado-Michaloud,Géraldine Folch,Fatena Bellahcene,Yan-Yan Wu,Elodie Gemrot,Xavier Brochet,Jérôme Lane,Laetitia Regnier,François Ehrenmann,Gérard Lefranc,Patrice Duroux +13 more
TL;DR: IMGT, the international ImMunoGeneTics information system, was created in 1989 by Marie-Paule Lefranc, Laboratoire d'ImmunoGénétique Moléculaire LIGM at Montpellier, France, in order to standardize and manage the complexity of immunogenetics data.
Journal ArticleDOI
IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis
TL;DR: IMGT/V-QUEST is the highly customized and integrated system for the standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) rearranged nucleotide sequences.
Journal ArticleDOI
IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains.
Marie-Paule Lefranc,Christelle Pommié,Quentin Kaas,Elodie Duprat,Nathalie Bosc,Delphine Guiraudou,Christelle Jean,Manuel Ruiz,Isabelle Da Piédade,Mathieu Rouard,Elodie Foulquier,Valérie Thouvenin,Gérard Lefranc +12 more
TL;DR: The IMGT unique numbering is, therefore, highly valuable for the comparative, structural or evolutionary studies of the immunoglobulin superfamily (IgSF) domains, V-DOMAINs and C- DOMAINs of IG and TR in vertebrates, and V-LIKE-DOMains andC-LIke-DOMains of proteins other than IG andTR, in any species.